Inclusion Criteria:  Participated in Protocol FB401-01, completed through Week 20 visit and able to directly enroll into this (FB401-02) study Refrain from use of all other atopic dermatitis treatments, unless given permission by medical monitor  Exclusion Criteria:  Subject experienced a serious adverse event or severe adverse event attributable to study drug in Protocol FB401-01 Severe concomitant illness that, in the Investigator's opinion, would adversely affect subject participation in the study, whether medical or psychological Pregnant (or planning to become pregnant during the period of the study) or lactating females